Evidence map›Paper›PMID 33922820›Full record

ReviewBiomedicines2021

Role of MicroRNAs in Human Osteosarcoma: Future Perspectives.

Lola Llobat, Olivia Gourbault

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Cancers · 2024
    Article
  12. Review
  13. Review
  14. Article
  15. Possible Role of IL-6R/STAT3/MiRNA-34a Feedback Loop in Osteosarcoma.Asian Pacific journal of cancer prevention : APJCP · 2023
    Article
  16. How Does Nutrition Affect the Epigenetic Changes in Dairy Cows?Animals : an open access journal from MDPI · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. miRNA in Molecular Diagnostics.Bioengineering (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lola LlobatDepartment of Animal Production and Health, Public Veterinary Health and Food Science and Technology, Faculty of Veterinary Medicine, CEU Cardenal Herrera University, 46115 Alfara del Patriarca, Spain.ORCID 0000-0002-9806-9174
Olivia GourbaultAtlantia Veterinary Hospital, 44200 Nantes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is a rare form of cancer with high death rate but is one of the most frequent forms of bone cancer in children and adolescents. MiRNAs are small endogenous RNAs that regulate gene expression post-transcriptionally. The discovery of miRNAs could allow us to obtain an earlier diagnosis, predict prognosis and chemoresistance, and lead to the discovery of new treatments in different types of tumors, including OS. Despite the fact that there is currently only one clinical trial being carried out on a single miRNA for solid tumors, it is very probable that the number of clinical trials including miRNAs as prognostic and diagnostic biomarkers, as well as potential therapeutic targets, will increase in the near future. This review summarizes the different miRNAs related to OS and their possible therapeutic application.

Indexed as

biomarkershuman osteosarcomahuman sarcomamolecular oncology

Identifiers

PMID33922820
PMCPMC8146779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.